MRD-guided treatment cessation in multiple myeloma

Minimal residual disease (MRD) entered the scientific lexicon in 1973, with the promise of immunotherapy to reduce tumour burden so that only MRD remained.1 The term has since taken on a different meaning in multiple myeloma to denote the persistence of low-level disease.